# A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

> **NCT04180982** · PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 84 (estimated)

## Conditions studied

- Hyperuricemia

## Interventions

- **DRUG:** SHR4640 dose1 plus Febuxostat dose1
- **DRUG:** SHR4640 dose1 plus Febuxostat dose2
- **DRUG:** SHR4640 dose2 plus Febuxostat dose3

## Key facts

- **NCT ID:** NCT04180982
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-03
- **Primary completion:** 2020-07-30
- **Final completion:** 2020-08-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2019-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04180982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04180982, "A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04180982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*